AR059902A2 - Complejo de factor viii/vwf o factor viii:c - Google Patents

Complejo de factor viii/vwf o factor viii:c

Info

Publication number
AR059902A2
AR059902A2 ARP070101059A ARP070101059A AR059902A2 AR 059902 A2 AR059902 A2 AR 059902A2 AR P070101059 A ARP070101059 A AR P070101059A AR P070101059 A ARP070101059 A AR P070101059A AR 059902 A2 AR059902 A2 AR 059902A2
Authority
AR
Argentina
Prior art keywords
factor
viii
vwf
factor viii
complex
Prior art date
Application number
ARP070101059A
Other languages
English (en)
Inventor
Arthur Mitterer
Bernhard Fischer
Oyvind L Schonberger
Kathrin Thomas-Urban
Friedrich Dorner
Jonhann Eibl
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3487946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059902(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of AR059902A2 publication Critical patent/AR059902A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a un complejo de factor VIII/vWF obtenible mediante cromatografía de intercambio cationico. Reivindicacion 1: Un complejo Factor VIII/factor von Willebrand (Factor VIII/vWF) caracterizado porque contiene multímeros de alto peso molecular que tienen una actividad vWF específica de al menos 66 U/mg de proteína y una actividad específica de Factor VIII de al menos 500 U/mg de proteína.
ARP070101059A 1997-02-27 2007-03-15 Complejo de factor viii/vwf o factor viii:c AR059902A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0033897A AT406373B (de) 1997-02-27 1997-02-27 Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie

Publications (1)

Publication Number Publication Date
AR059902A2 true AR059902A2 (es) 2008-05-07

Family

ID=3487946

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980100835A AR010121A1 (es) 1997-02-27 1998-02-25 MÉTODO DE RECUPERACIoN DE COMPLEJO DE FACTOR VIII/FACTOR DE VON WILLEWBRAND (COMPLEJO DE FACTOR VIII/VWF) MEDIANTE CROMATOGRAFíA DE INTERCAMBIO CATIoNICO.
ARP070101059A AR059902A2 (es) 1997-02-27 2007-03-15 Complejo de factor viii/vwf o factor viii:c

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980100835A AR010121A1 (es) 1997-02-27 1998-02-25 MÉTODO DE RECUPERACIoN DE COMPLEJO DE FACTOR VIII/FACTOR DE VON WILLEWBRAND (COMPLEJO DE FACTOR VIII/VWF) MEDIANTE CROMATOGRAFíA DE INTERCAMBIO CATIoNICO.

Country Status (11)

Country Link
US (3) US6831159B1 (es)
EP (1) EP0971958B2 (es)
JP (1) JP4250771B2 (es)
AR (2) AR010121A1 (es)
AT (2) AT406373B (es)
AU (1) AU744919B2 (es)
CA (1) CA2282841C (es)
DE (1) DE59814211D1 (es)
ES (1) ES2306471T5 (es)
NO (2) NO324902B1 (es)
WO (1) WO1998038220A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
ES2298096B1 (es) 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
DK2349314T3 (da) 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
CN106008697B (zh) * 2009-08-20 2020-08-04 百深公司 纯化vwf以增加非-脂质包封的病毒的去除
KR101808751B1 (ko) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
US9029517B2 (en) 2010-07-30 2015-05-12 Emd Millipore Corporation Chromatography media and method
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
KR101969515B1 (ko) * 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
US9534037B2 (en) 2011-08-02 2017-01-03 Baxalta GmbH Systems and methods to increase protein yield from recombinant manufacturing processes
BR122019026149A8 (pt) 2012-06-15 2022-06-28 Commw Scient Ind Res Org Célula hospedeira, processo de produzir um lipídio de planta extraído, método de produzir semente, farinha de semente, método para produzir um produto alimentício, uso e processo para produzir ésteres de etila
EP2925777B1 (en) * 2012-11-30 2019-05-01 Centre for Bioseparation Technology-VIT Monolith-based pseudo-bioaffinity purification methods for factor viii and applications thereof
US10246485B2 (en) 2013-11-08 2019-04-02 Csl Limited Method to concentrate von willebrand factor or complexes thereof
PE20170253A1 (es) 2013-12-18 2017-04-14 Nuseed Pty Ltd Lipido que comprende acidos grasos poliinsaturados de cadena larga
AU2015281791A1 (en) 2014-06-27 2017-01-12 Commonwealth Scientific And Industrial Research Organisation Lipid comprising docosapentaenoic acid
US10449517B2 (en) 2014-09-02 2019-10-22 Emd Millipore Corporation High surface area fiber media with nano-fibrillated surface features
US20170298091A1 (en) 2014-12-08 2017-10-19 Emd Millipore Corporation Mixed Bed Ion Exchange Adsorber
DK3648788T3 (da) 2017-07-07 2024-08-19 Takeda Pharmaceuticals Co Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf
PT3648787T (pt) 2017-07-07 2025-01-20 Takeda Pharmaceuticals Co Tratamento de doentes com doença de von willebrand grave submetidos a cirurgia eletiva por administração de vwf recombinante
BR112021015068A2 (pt) 2019-02-01 2021-10-05 Takeda Pharmaceutical Company Limited Métodos de tratamento profilático usando vwf recombinante (rvwf)
CN114106145B (zh) * 2021-10-22 2023-09-01 山东泰邦生物制品有限公司 一种血源人凝血因子ⅷ/血管性血友病因子复合物生产工艺

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
GB8403473D0 (en) * 1984-02-09 1984-03-14 Special Trustees For St Thomas Purification of factor viii
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
FR2651437A1 (fr) * 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
NZ237244A (en) 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
IT1256622B (it) † 1992-12-04 1995-12-12 Sclavo Spa Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale.
CA2159044A1 (en) * 1994-09-26 1996-03-27 Falko-Guenter Falkner Method of quantitating nucleic acids
AT401270B (de) * 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT403765B (de) * 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
CA2251558C (en) 1996-04-12 2005-11-22 Immuno Aktiengesellschaft Highly purified factor viii complex
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie

Also Published As

Publication number Publication date
EP0971958A1 (de) 2000-01-19
US20020058625A1 (en) 2002-05-16
US6831159B1 (en) 2004-12-14
ATA33897A (de) 1999-09-15
AR010121A1 (es) 2000-05-17
ES2306471T3 (es) 2008-11-01
NO326257B1 (no) 2008-10-27
NO324902B1 (no) 2007-12-27
CA2282841A1 (en) 1998-09-03
DE59814211D1 (de) 2008-05-21
CA2282841C (en) 2008-12-02
JP4250771B2 (ja) 2009-04-08
AU744919B2 (en) 2002-03-07
AT406373B (de) 2000-04-25
WO1998038220A1 (de) 1998-09-03
NO994137D0 (no) 1999-08-26
EP0971958B2 (de) 2012-02-08
US7648958B2 (en) 2010-01-19
ES2306471T5 (es) 2012-06-07
ATE391728T1 (de) 2008-04-15
EP0971958B1 (de) 2008-04-09
NO20071357L (no) 1999-08-26
AU6080698A (en) 1998-09-18
NO994137L (no) 1999-08-26
US20050239171A1 (en) 2005-10-27
JP2001517212A (ja) 2001-10-02
US6953837B2 (en) 2005-10-11

Similar Documents

Publication Publication Date Title
Furlan et al. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers.
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
ATE245442T1 (de) Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose
ES2196031T3 (es) Derivados peptidicos terapeutico.
YU53098A (sh) Preparat koncentrovanog antitela
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
LU91448I2 (fr) "panitumumab"
ATE230611T1 (de) Pharmazeutische zusammensetzungen mit plasmaproteinen
MX9305729A (es) Formulas de proteinas de liberacion sostenida.
UA27763C2 (uk) Рекомбінантна молекула днк, що кодує молекулу адгезії icam-3, молекула адгезії icam-3, антитіло, здатне зв'язуватись з такою молекулою, фармацевтична композиція
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
DK0503648T3 (da) CD2-bindingsdomæne af lymfocytfunktion-associeret antigen 3
FI943745L (fi) Koostumuksia ja menetelmiä proteiinin rakenteen määrityksiin
PT672138E (pt) Proteinas quimericas coagulantes
EP0695171A1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
PT523395E (pt) Regioes sero-reactivas na proteina e1 e e2 de hpv 16
FI913470A0 (fi) Multimer form av receptorprotein hos humant rhinovirus.
BR9811948A (pt) Secretores de hormÈnio do crescimento
ES2181501T3 (es) Composicion cosmetica.
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
DE69127334D1 (de) Verabreichung von Mitteln
FR2717808B1 (fr) Composition cosmétique stable à la lumière.
ATE69727T1 (de) Zusammensetzung zur behandlung von an haemophilia- a-inhibitor leidenden kranken.
MX9302614A (es) Receptor de glutamato metabotropico humano y compuestos de dna relacionados.

Legal Events

Date Code Title Description
FB Suspension of granting procedure